These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 32860715)
1. Extended follow-up of CD4 Gaiolla R; Hartley S; Beech A; Knight H; Smith D; Bishton M; Fox CP; Martinez-Calle N Hematol Oncol; 2021 Feb; 39(1):137-140. PubMed ID: 32860715 [No Abstract] [Full Text] [Related]
2. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. García Muñoz R; Izquierdo-Gil A; Muñoz A; Roldan-Galiacho V; Rabasa P; Panizo C Ann Hematol; 2014 Nov; 93(11):1879-87. PubMed ID: 24951124 [TBL] [Abstract][Full Text] [Related]
3. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M; Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421 [TBL] [Abstract][Full Text] [Related]
4. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156 [TBL] [Abstract][Full Text] [Related]
5. Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma. Yutaka T; Ito S; Ohigashi H; Naohiro M; Shimono J; Souichi S; Teshima T Leuk Lymphoma; 2015; 56(11):3216-8. PubMed ID: 25760636 [No Abstract] [Full Text] [Related]
6. Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. Gentile M; Shanafelt TD; Reda G; Mauro FR; Zirlik K; Ciolli S; Laurenti L; Del Principe MI; Rossi D; Di Renzo N; Molica S; Angrilli F; Coscia M; Chiarenza A; Giordano A; Cutrona G; Chaffee KG; Parikh SA; Uccello G; Innocenti I; Tripepi G; D'Arrigo G; Vigna E; Recchia AG; Herishanu Y; Shvidel L; Tadmor T; Cortelezzi A; Del Poeta G; Gaidano G; Di Raimondo F; Neri A; Ferrarini M; Foà R; Polliack A; Morabito F Leukemia; 2018 Aug; 32(8):1869-1873. PubMed ID: 29588545 [No Abstract] [Full Text] [Related]
7. Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia. Flinn IW; Cherry MA; Maris MB; Matous JV; Berdeja JG; Patel M Am J Hematol; 2019 Dec; 94(12):1325-1334. PubMed ID: 31490009 [TBL] [Abstract][Full Text] [Related]
8. A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities. Danilov AV; Lewis LD; Lansigan F; Roudaia L; Findley DL; Jones SY; Highhouse B; Beaulieu BB; Brown JR Br J Haematol; 2017 Sep; 178(5):820-823. PubMed ID: 27377970 [No Abstract] [Full Text] [Related]
9. Rituximab/Bendamustine treatment of chronic lymphatic leukemia leads to sustained remission of antiphospholipid antibodies. Ames PR; Merashli M; Gentile F Eur J Immunol; 2019 Jun; 49(6):969-970. PubMed ID: 30893471 [No Abstract] [Full Text] [Related]
10. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ; Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274 [TBL] [Abstract][Full Text] [Related]
11. Recurrent and partially reversible cardiomyopathy occurring during treatment with bendamustine and rituximab. Mulay S; Boruchov A Leuk Lymphoma; 2015 Mar; 56(3):805-7. PubMed ID: 24913498 [No Abstract] [Full Text] [Related]
12. Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial. Montillo M; Illés Á; Robak T; Pristupa AS; Wach M; Egyed M; Delgado J; Jurczak W; Morschhauser F; Schuh A; Eradat H; Shreay S; Barrientos JC; Zelenetz AD Health Qual Life Outcomes; 2019 Nov; 17(1):173. PubMed ID: 31729982 [TBL] [Abstract][Full Text] [Related]
13. Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis. Martínez-Calle N; Hartley S; Ahearne M; Kasenda B; Beech A; Knight H; Balotis C; Kennedy B; Wagner S; Dyer MJS; Smith D; McMillan AK; Miall F; Bishton M; Fox CP Br J Haematol; 2019 Mar; 184(6):957-968. PubMed ID: 30548597 [TBL] [Abstract][Full Text] [Related]
14. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Jain N; Balakrishnan K; Ferrajoli A; O'Brien SM; Burger JA; Kadia TM; Cortes JE; Ayres ML; Tambaro FP; Keating MJ; Gandhi V; Wierda WG Oncotarget; 2017 Mar; 8(13):22104-22112. PubMed ID: 27655665 [TBL] [Abstract][Full Text] [Related]
15. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405 [TBL] [Abstract][Full Text] [Related]
16. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Michallet AS; Aktan M; Hiddemann W; Ilhan O; Johansson P; Laribi K; Meddeb B; Moreno C; Raposo J; Schuh A; Ünal A; Widenius T; Bernhardt A; Kellershohn K; Messeri D; Osborne S; Leblond V Haematologica; 2018 Apr; 103(4):698-706. PubMed ID: 29419437 [TBL] [Abstract][Full Text] [Related]
17. Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status. Ziolkowska E; Wolowiec D; Karpinski P; Blonski JZ; Lech-Maranda E; Borowiec M; Balcerczak E; Sasiadek M; Robak T; Korycka-Wolowiec A Leuk Lymphoma; 2019 Jun; 60(6):1409-1419. PubMed ID: 30187811 [TBL] [Abstract][Full Text] [Related]
18. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature. Kleeberg UR; Linde H; Günther G; Tessen HW; Kersting M Anticancer Res; 2016 Jun; 36(6):2827-38. PubMed ID: 27272794 [TBL] [Abstract][Full Text] [Related]